Answers are grounded in this paper and cite their sources.
Clarithromycin is a macrolide antibiotic commonly indicated for use in upper and lower respiratory infections and has a well established safety and efficacy profile. Rare case reports of fatal progressive cholestatic and fulminant hepatitis from clarithromycin have been described but the spectrum of liver disease and its characteristics are not well defined. We describe a case of clarithromycin-induced liver injury notable for the combination of cholestasis with associated lobular hepatitis and complete resolution of symptoms on withdrawal. Health care providers should be aware of a rare idiosyncratic cholestatic hepatitis caused by this drug which may require immediate discontinuation and careful monitoring.
No takes yet. Share an insight, caveat, or question.
A 2007 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: